insights_auto
Miksi 4142 on laskenut 6,62%?
Tutustu tarkemminchevron_right
4142:TPE
Adimmune Corp
14,80 TWD
arrow_downward
−6,62%(−1,05) 1 pv
20.11., 13.30.09 UTC+8 · TWD
search
Kaikki symbolit
| Symboli | Hinta | Muutos | Muutos (%) |
|---|
insights_autoLuodaan huippuvinkkejä: 4142…
Avaa
15,75 TWD
Korkea
15,75 TWD
Matala
14,80 TWD
Markkina-arvo
6,36 mrd.
Keskimääräinen volyymi
1,13 milj.
Volyymi
1,63 milj.
P/E-luku
85,76
52 viikon ylin
21,50 TWD
52 viikon alin
14,80 TWD
Osakekohtainen tulos (EPS)
0,17 TWD
Liikkeellä olevat osakkeet
235,29 milj.
Työntekijöiden lukumäärä
564
Avaa
15,75 TWD
Korkea
15,75 TWD
Matala
14,80 TWD
Markkina-arvo
6,36 mrd.
Keskimääräinen volyymi
1,13 milj.
Volyymi
1,63 milj.
P/E-luku
85,76
52 viikon ylin
21,50 TWD
52 viikon alin
14,80 TWD
Osakekohtainen tulos (EPS)
0,17 TWD
Liikkeellä olevat osakkeet
235,29 milj.
Työntekijöiden lukumäärä
564
Uutiset
Verkkolähteistä ja uutiskumppaneilta
The Motley Fool
·
1 tunti sitten
Bitcoin Is 35% Below Its 52-Week High While the S&P 500 Is Up. Here’s What That Says About the Digital Gold Thesis.
MarketWatch
·
49 minuuttia sitten
Here’s what happened next after previous times the S&P 500 losing streak reached six sessions
Benzinga
·
47 minuuttia sitten
Stock Market Today: Dow Jones, S&P 500 Futures Fall as Trump Weighs Iran Decision— INTU, ROST, KEYS in Focus
MarketForces Africa
·
2 tuntia sitten
S&P 500, Nasdaq, Dow Jones Dip Amidst Anthropic IPO Debut
Profiili
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
Tietoa: Adimmune Corp
Toimitusjohtaja-
Työntekijät564
Perustamispäivä1965
Päätoimipaikka-
ToimialaHealth Care
Toimiala-
Sivustoadimmune.com.tw